A randomised trial of Curcuma longa for treating symptoms and effusion-synovitis of knee osteoarthritis.

niversity of Tasmania0 个研究点目标入组 70 人开始时间: 2018年1月19日最近更新: 2019年7月15日

适应症

试验速览

暂无简介。

•1.Aged over 40 years old.
•2.Men and women with significant knee pain on most days (defined as a VAS >40mm).
•3.Knee effusion–synovitis on US (>=4mm thickness measure).
•4.Meet American College of Rheumatology (ACR) clinical criteria for knee OA confirmed by a clinician.

•1.Inability to have an MRI (claustrophobia, metal in eyes or selected knee, pacemakers).
•2.Severe knee OA (joint space narrowing (JSN) on X-ray of Grade 3 using the Osteoarthritis Research Society International (OARSI) atlas).
•3.Unwillingness to stop taking Curcuma longa medications 2 weeks prior to randomization
•4.Other forms of inflammatory arthritis (especially rheumatoid arthritis and gout).
•5.Significant knee injury within the last 6 months.
•6.Arthroscopy or open surgery in the index knee in the last 12 months, or planned.
•7.Injections of corticosteroids (last 3 months) or hyaluronic acid (last 6 months) in the index knee.
•8.Pregnancy or breastfeeding.
•9.Use of any investigational drug(s) and/or devices within 30 days prior to randomisation
•10.Presence of any serious medical illness that may preclude 24 week follow up.
•11.Inability to provide informed consent.
•12. Study Investigators consider the patient is otherwise unsuitable for the study including the assessment of kidney function for a contrast-enhanced MRI study.

发起方

niversity of Tasmania